The potential clinical use of ER-β in BC endocrine therapy has been investigated in retrospective studies, and ER-β positivity has been associated with significantly better survival in patients with ER-α-negative, progesterone receptor (PgR)-negative and triple-negative tumors treated with adjuvant tamoxifen therapy. This evidence concerns the gene PGR and breast cancer.